290 related articles for article (PubMed ID: 23423257)
1. Antineutrophil cytoplasm antibody-associated vasculitis: recent developments.
Furuta S; Jayne DR
Kidney Int; 2013 Aug; 84(2):244-9. PubMed ID: 23423257
[TBL] [Abstract][Full Text] [Related]
2. The future of ANCA-associated vasculitis.
Holle JU; Wieczorek S; Gross WL
Rheum Dis Clin North Am; 2010 Aug; 36(3):609-21. PubMed ID: 20688253
[TBL] [Abstract][Full Text] [Related]
3. Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Update: Genetic Pathogenesis.
Li W; Huang H; Cai M; Yuan T; Sheng Y
Front Immunol; 2021; 12():624848. PubMed ID: 33841406
[TBL] [Abstract][Full Text] [Related]
4. Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients?
Tesar V; Hruskova Z
Expert Opin Pharmacother; 2015; 16(11):1683-702. PubMed ID: 26149512
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Lionaki S; Fragoulis GE; Venetsanopoulou A; Vlachoyiannopoulos P; Boletis JN; Tzioufas AG
Clin Exp Rheumatol; 2017; 35 Suppl 103(1):155-164. PubMed ID: 28134075
[TBL] [Abstract][Full Text] [Related]
6. Increased levels of neutrophil extracellular trap remnants in the circulation of patients with small vessel vasculitis, but an inverse correlation to anti-neutrophil cytoplasmic antibodies during remission.
Söderberg D; Kurz T; Motamedi A; Hellmark T; Eriksson P; Segelmark M
Rheumatology (Oxford); 2015 Nov; 54(11):2085-94. PubMed ID: 26170375
[TBL] [Abstract][Full Text] [Related]
7. Maintenance treatment of ANCA-associated vasculitides.
Guillevin L
Clin Exp Rheumatol; 2017; 35 Suppl 103(1):199-201. PubMed ID: 28406765
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis and treatment of ANCA-associated vasculitides.
Kallenberg CG
Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S11-4. PubMed ID: 26457917
[TBL] [Abstract][Full Text] [Related]
9. Anti-neutrophil Cytoplasmic Antibodies (ANCA) as Disease Activity Biomarkers in a "Personalized Medicine Approach" in ANCA-Associated Vasculitis.
Osman MS; Tervaert JWC
Curr Rheumatol Rep; 2019 Dec; 21(12):76. PubMed ID: 31879818
[TBL] [Abstract][Full Text] [Related]
10. Plasma exchange in antineutrophil cytoplasm antibody-associated vasculitis.
Walsh M
Curr Opin Nephrol Hypertens; 2014 Nov; 23(6):555-9. PubMed ID: 25144513
[TBL] [Abstract][Full Text] [Related]
11. Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease.
Kambas K; Chrysanthopoulou A; Vassilopoulos D; Apostolidou E; Skendros P; Girod A; Arelaki S; Froudarakis M; Nakopoulou L; Giatromanolaki A; Sidiropoulos P; Koffa M; Boumpas DT; Ritis K; Mitroulis I
Ann Rheum Dis; 2014 Oct; 73(10):1854-63. PubMed ID: 23873874
[TBL] [Abstract][Full Text] [Related]
12. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X
Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313
[TBL] [Abstract][Full Text] [Related]
13. [Review article: Antineutrophil cytoplasmic antibody in small vessel vasculitis].
Nakano H; Ozaki S
Rinsho Byori; 2010 May; 58(5):480-9. PubMed ID: 20560457
[TBL] [Abstract][Full Text] [Related]
14. Seasonal Influence on the Risk of Relapse at a Rise of Antineutrophil Cytoplasmic Antibodies in Vasculitis Patients with Renal Involvement.
Kemna MJ; Cohen Tervaert JW; Broen K; Timmermans SAMEG; van Paassen P; Damoiseaux JGMC
J Rheumatol; 2017 Apr; 44(4):473-481. PubMed ID: 28202741
[TBL] [Abstract][Full Text] [Related]
15. Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis.
Csernok E; Lamprecht P; Gross WL
Curr Opin Rheumatol; 2010 Jan; 22(1):43-8. PubMed ID: 19770659
[TBL] [Abstract][Full Text] [Related]
16. [Pathology of the ANCA-associated vasculitides].
Ferrario F; Vanzati A; Pilla D; Pagni F
G Ital Nefrol; 2013; 30(2):. PubMed ID: 23832458
[TBL] [Abstract][Full Text] [Related]
17. ANCA-associated vasculitis: diagnostic and therapeutic strategy.
Ozaki S
Allergol Int; 2007 Jun; 56(2):87-96. PubMed ID: 17460438
[TBL] [Abstract][Full Text] [Related]
18. [Clinical practice guideline for ANCA-associated vasculitis with renal involvement].
Vazquez V; Fayad A; González G; Smuclir Quevedo A; Robaina Sindín J;
Medicina (B Aires); 2015; 75 Suppl 1():1-38. PubMed ID: 26738202
[TBL] [Abstract][Full Text] [Related]
19. Ectopic Relapse of Anti-neutrophil Cytoplasmic Antibody-associated Pituitary Vasculitis with No Elevation of Anti-neutrophil Cytoplasmic Antibodies after Renal Remission.
Muto R; Inagaki K; Sato N; Sameshima T; Nagakura Y; Baba S; Kato N; Maruyama S; Akahori T
Intern Med; 2020 Dec; 59(24):3187-3193. PubMed ID: 32788533
[TBL] [Abstract][Full Text] [Related]
20. Can antineutrophil cytoplasmic antibody levels be used to inform treatment of pauci-immune vasculitis?
Fussner LA; Specks U
Curr Opin Rheumatol; 2015 May; 27(3):231-40. PubMed ID: 25775187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
